セッション詳細
[D1-A5]バイオロジクス開発の進展：免疫原性評価の包括的かつ最適なアプローチ
2025年3月3日(月) 17:35 〜 19:05
中ホール(2階)
座長:清水 浩之(田辺三菱製薬株式会社)、原 久典(B2S Life Sciences)
[D1-A5-01]Crafting a Science-Driven Immunogenicity Risk Assessment
*Joleen T White1 (1. Bill & Melinda Gates Medical Research Institute (Gates MRI))
[D1-A5-02]Telling the Whole Story: The Integrated Summary of Immunogenicity
*Paul D Chamberlain1 (1. Immunogenicity Integrated Platform)
[D1-A5-03]Update on Current Discussions in and Recommendations from the EBF on ADA Related Themes (1-Tier, Drug Tolerance, CoU for and beyond Biomarkers)
*Kyra J Cowan1 (1. European Bioanalysis Forum)